US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.80

+0.11000.28%

Volume:45.20K

Turnover:1.75M

Market Cap:353.86M

PE:- -

High:38.94

Open:38.78

Low:38.70

Close:38.69

52wk High:39.80

52wk Low:30.66

Shares:9.12M

Float Shares:9.12M

Volume Ratio:0.72

T/O Rate:0.50%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved

Press Release: Antengene Announces 2026 Interim Results: Achieves First

The $3 billion short squeeze: anatomy of crypto’s biggest liquidation event since 2021

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ORR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.8,"timestamp":1787597359342,"preClose":38.69,"halted":0,"volume":45201,"delay":0,"changeRate":0.0028431119152235573,"floatShares":9120000,"shares":9120000,"eps":0,"marketStatus":"Trading","change":0.11,"latestTime":"08-24 14:50:32 EDT","open":38.78,"high":38.935,"low":38.695,"amount":1754703.72402,"amplitude":0.006203,"askPrice":38.87,"askSize":234,"bidPrice":38.81,"bidSize":2,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":38.69,"sharesOutstanding":12900000,"nav":38.21,"aum":348475200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.69,"preClose":38.69,"latestTime":"19:30 EDT","volume":11,"amount":425.59,"timestamp":1787355007198,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.723347,"impliedVol":0.1403,"impliedVolPercentile":0.5063},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9120000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.723347,"shares":9120000,"dividePrice":0,"high":38.935,"amplitude":0.006203,"preClose":38.69,"low":38.695,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.8,"committee":-0.983051,"eps":0,"divideRate":0,"volume":45201,"delay":0,"ttmEps":0,"open":38.78,"prevYearClose":34.16,"prevWeekClose":38.69,"prevMonthClose":38.79,"prevQuarterClose":36.32,"fiveDayClose":38.09,"twentyDayClose":37.26,"sixtyDayClose":36.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661695272","title":"Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2661695272","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661695272?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:32","pubTimestamp":1787581920,"startTime":"0","endTime":"0","summary":"BEIJING, Aug. 24, 2026  -- InnoCare Pharma , a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business highlights for the six months ended 30 June 2026.InnoCare delivered robust revenue growth and strengthened profitability in the first half of 2026, driven by strong commercial execution and global business development collaborations. In the first half of 2026, the Company's revenue grew by 55.5% year-on-year to RMB 1.1 billion, and profit reached RMB 239.7 million, a turnaround from a loss in the same period last year. These results reflect the successful implementation of the Company's strategy driven by innovation, commercialization and globalization.In the first half of 2026, InnoCare continued to accelerate innovation, achieving a series of key milestones.-- 1 NDA approval: Orelabrutinib was approved in Australia.-- 2 NDA acceptances: The NDA applications for orelabrutinib in primary. immune thrombocytopenia  a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","MTD","IE00B5TLWC47.USD","IND","BK4588","CR","BK4077","ORR","ITP","SLE","PFS","BK4195","IE00BFXG0V08.USD","09969","BK4585","LU2413666426.HKD","BK4211","BK1574","BK4548","BK4161","BK4121","BK4199","LU1093756325.SGD","LU1721428933.USD","BK1161","BK4567","IE00BYQQ9H92.USD","LU0347712357.USD","LU2211817866.USD","LU1093756168.USD","LU2413666699.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661410992","title":"Press Release: Antengene Announces 2026 Interim Results: Achieves First","url":"https://stock-news.laohu8.com/highlight/detail?id=2661410992","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661410992?lang=en_us&edition=fundamental","pubTime":"2026-08-24 09:00","pubTimestamp":1787533200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Aug. 23, 2026 /PRNewswire/ -- Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B66KJ199.SGD","COAL","BK4604","BK1583","R","LU0963586101.USD","IE00B7SZL793.SGD","06996","BK4187","TM","BK4099","BK1191","BK4555","CR","CRS","XAR","HCC","ORR","BK4585","BK4022","03160","BK1574","BK4006","LU2065731478.USD","BK4161","BK4232","IE0031619046.USD","IE00B19Z4B17.USD","PYZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661525287","title":"The $3 billion short squeeze: anatomy of crypto’s biggest liquidation event since 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2661525287","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661525287?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:25","pubTimestamp":1787289926,"startTime":"0","endTime":"0","summary":"Six weeks of bearish positioning ended in 24 hours. Here is how the trade unwound, who got caught, and whether the squeeze has legs.More than $3 billion in leveraged short positions were liquidated across crypto derivatives markets on Aug 19 and 20, 2026, making it the eighth largest liquidation event on record and the largest concentrated short squeeze since November 2021.Bitcoin climbed from an intraday low near $64,100 to a peak above $72,000, while Ethereum surged roughly 18% in 24 hours, its strongest single day move since March 2024.The U.S. Treasury doubled the maximum size of its liquidity support buyback operations for long dated bonds from $2 billion to $4 billion per operation, compressing yields and pushing risk assets higher.Binance absorbed approximately $518 million in liquidations, Hyperliquid roughly $513 million, and Bybit around $303 million, with short positions accounting for 92% of all forced closures.Then, over the span of 24 hours, it went violently higher.Bitco","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/3-billion-short-squeeze-anatomy-crypto-biggest-liquidation-2021-2/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/3-billion-short-squeeze-anatomy-crypto-biggest-liquidation-2021-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["YETH","DWSH","GDLC","HDGE","BTC.USD.CC","LITU","FFLS","EETH","BITW","ETHT","FTLS","BERZ","EZET","LFGY","IBIT","BITQ","GMEC","HELS","09042","ETH","NCIQ","ETHA","ETHW","MEMY","QETH","STCE","ETU","RIVC","DIME","TON.USD.CC","ORR","HFEQ","OSSL","FETH","BTC.USD.HKCC","ETHU","WX","EVNT","CRPT","ETHV","CLSE","ETHD","TEKX","ETHE","LSEQ","SHRT","BTF","LBAY","DAPP","BKCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660770364","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660770364","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660770364?lang=en_us&edition=fundamental","pubTime":"2026-08-20 10:53","pubTimestamp":1787194380,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  19, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the full abstract of the Phase II clinic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/20/3348072/0/en/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-abstract-published-by-wclc-extended-follow-up-shows-continued-efficacy-improvement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBXA","BFJL","COAL","BPI","XHB","CBOO","DFII","IBIT","CBXY","BRRR","BTCC","CBTO","BITO","BTCW","BTCI","ORR","CBTJ","SBIT","PD","BTC","BTCZ","ARKB","HODL","BTCO","OC","BAGY","GBTC","CBXJ","CBTA","YBTC","BTCL","BITY","QBF","FBTC","ODD","MAXI","BETH","EZBC","BETE","BITX","DEFI","BITI","CBOA","BTRN","BFAP","BTF","HCC","PFS","XBTY","BITB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":34,"pageCount":1,"totalSize":133,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}